BioCardia (BCDA)
(Delayed Data from NSDQ)
$2.54 USD
-0.44 (-14.77%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.57 +0.03 (1.18%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
BioCardia, Inc. [BCDA]
Reports for Purchase
Showing records 1 - 20 ( 60 total )
Company: BioCardia, Inc.
Industry: Medical - Drugs
Protocol Tweak in Cell Population Analysis Looks to Enhance CardiAMP?s Efficiency in CardiAMP HF II
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
2Q24 Results; Pushing for CardiAmp HF II Enrollment With Support From CardiAMP HF Results; Split-Adjusted Target to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
CardiAMP HF II Initiates Recruitment of High-Level NTproBNP Population; Enrollment Completion Expected in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
Company: BioCardia, Inc.
Industry: Medical - Drugs
Raises Capital but It?s Less Than a Million, Stock Back to Its Lows CardiAMP Trial Pushes Forward in the Wake of the Last Failed Trial
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: BioCardia, Inc.
Industry: Medical - Drugs
Company: BioCardia, Inc.
Industry: Medical - Drugs
CardiAMP Heart Failure II Trial Gets the Green Light; Data Readout Expected in 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
3Q23 Results; Awaiting Regulatory Decisions and Addressing Cash Resources; PMDA and FDA Updates Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
High Level NT-proBNP Population is the Focus of the Anticipated New CardiAMP HF Trial II
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
Unsatisfactory Phase 3 CardiAMP HF Interim Look; Potential New Trial With Modified Protocol; Target Reduced to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
The 250-patient randomized controlled study is unlikely to meet its primary three-tiered FS efficacy endpoint
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: BioCardia, Inc.
Industry: Medical - Drugs
Post DSMB Pausing Trial: Reports 2nd Qtr. Loss of $3.4M We Expect the Company to Raise Capital Again, soon
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: BioCardia, Inc.
Industry: Medical - Drugs
2Q23 Results; All Efforts Into Cardiac Programs; Uncertain CardiAMP HF Path Forward in the U.S.
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
Company: BioCardia, Inc.
Industry: Medical - Drugs
DSMB Pauses CardiAMP HF Enrollment Pending 12-Month Outcomes Analysis For All Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
Submission of CardiAMP Cell Therapy to the PMDA Accomplished; Initial Feedback Expected September 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
A Curious Press Release Followed by a Raise
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: BioCardia, Inc.
Industry: Medical - Drugs
Adaptive SAP Aspires an Early CardiAMP HF Efficacy Readout; Upcoming DSMB Meeting Next Month
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioCardia, Inc.
Industry: Medical - Drugs
First Quarter Results: $4.8M in Cash Remaining
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: BioCardia, Inc.
Industry: Medical - Drugs
1Q23 Results; FDA Feedback on Revised CardiAMP HF Statistical Analysis Plan Nears
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J